A highlight of all our trial and research achievements this past month:
NABNEC enrolment closing December 2021
The NABNEC NETs clinical trial will be closing to patient enrolment 31 December 2021. This trial, led by Dr Lorraine Chantrill, is comparing carboplatin plus nab-paclitaxel versus carboplatin plus etoposide in improving disease response rates in NETs patients. If you have any patients who may be suitable for this trial, then find out more.
OXTOX recruits first Shoalhaven patient
Congratulations to Shoalhaven District Memorial Hospital for recruiting their first patient to the OXTOX colorectal cancer trial. With hospital restrictions improving and patients starting to come back for face-to-face consultations, we hope this will contribute to an increase in recruitment. OXTOX is a randomised phase II study to evaluate whether ibudilast decreases the severity of acute neuropathy and enables people with metastatic colorectal cancer to get more oxaliplatin before needing dose modifications for chemotherapy-induced peripheral neuropathy (CIPN).
MASTERPLAN featured in Journal of Clinical Oncology
The MASTERPLAN pancreatic cancer trial has featured in the Journal of Clinical Oncology’s article Value of Neoadjuvant Radiation Therapy in the Management of Pancreatic Adenocarcinoma, noted to be a major component to set the “future directions” for pancreas cancer. Led by Dr Andrew Oar and Professor Andrew Kneebone, this open trial is investigating whether stereotactic body radiotherapy, in addition to modern chemotherapy is superior to the current standard of chemotherapy alone in both the neoadjuvant and definitive setting.
MASTERPLAN protocol amendment
The MASTERPLAN protocol amendment V3.0 dated 25 August 2021 received HREC approval in September. Because of these changes, a higher rate of recruitment is anticipates at participating sites. The protocol amendment includes the following changes:
- Eligibility criteria
- Updated study schema to reflect feedback from investigators
- Clarification around CT scans and timing of scheduled visits
- Clarification around follow up for patients who progress prior to ending study treatment
- Addition of the microbiome sub-stud